tbuckley/cabot-search huggingface dataset:
Abstract P444: Long-Term Prognosis of Stress Cardiomyopathy in Women
Authors: Elena Salmoirago-Blotcher, Sandhya Reddy, Robert J Goldberg, Darleen M Lessard, Timothy Fitzgibbons, Joseph Bouchard, Sybil Crawford, Ira S Ockene, Gerard P Aurigemma
Journal: Circulation (2014)

Background: Transient Stress Cardiomyopathy (TSC) is a reversible condition mimicking acute myocardial infarction that frequently affects postmenopausal women and is often triggered by emotional or physical stress. Limited information is available about the long-term prognosis of this condition as previous studies were mostly case series and/or were unable to adjust for several confounding variables. The aim of this retrospective cohort study was to assess the post-hospital discharge prognosis of women diagnosed with TSC compared with historical ST-elevation myocardial infarction (STEMI) female controls. The principal study outcome was a composite of cardiovascular (CV) hospital readmissions and death from any cause. Methods: Cases were identified by reviewing the charts of consecutive women hospitalized at UMass Memorial Medical Center in Worcester, MA, with an ICD-9 code of 429.83 (Takotsubo cardiomyopathy) from 01/2002 until 06/2012. To be eligible, cases had to fulfill all Mayo clinic criteria for TSC. Controls were randomly selected (2:1 ratio) among women with a validated diagnosis of STEMI enrolled in the Worcester Heart Attack Study during the same period. Clinical characteristics and information about CV readmissions and death were abstracted from the medical record. Survival curves were generated by the Kaplan-Meier method. Log-rank statistics was used to compare survival curves. Risk of death or CV readmissions (with the STEMI category as the referent) was estimated from multivariate Cox proportional hazard regression models adjusted for variables associated with the composite outcome. Results: Out of 356 consecutive women hospitalized with an ICD-9 code of 429.83 (Takotsubo cardiomyopathy), 50 met Mayo diagnostic criteria. Baseline age was 65±14 years in TSC cases and 71 ±15 in STEMI controls (n=100). The prevalence of coronary risk factors, and of a history of angina, stroke and heart failure, was lower among TSC cases vs. controls. At admission, TSC women had lower peak CK, troponin I levels and SBP values; mean (angiogram) ejection fraction was 0.32 in TSC and 0.47 in STEMI women. TSC cases were less frequently prescribed aspirin, beta-blockers, lipid lowering agents and ACE inhibitors at hospital discharge. Over an overall average follow-up of 2 years, incidence rates of the composite outcome were 140/1,000 person-years among women with TSC and 347/1,000 person-years among those with STEMI. In multivariate adjusted models, the hazard ratio for the composite endpoint in TSC vs. STEMI women was 0.50 (CI: 0.26,0.98). Conclusion: Women diagnosed with TSC had a significantly better post-discharge prognosis than women with STEMI. However, mortality and CV readmissions rates among TSC women were relatively high, indicating that TSC is not a benign condition.
Abstract 11701: The Ten Year Prognostic Value of Zero and Minimal Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Parag H Joshi, Michael J Blaha, Matthew J Budoff, Michael Miedema, Robyn McClelland, Joao Lima, Arthur Agatston, Ron Blankstein, Roger Blumenthal, Khurram Nasir
Journal: Circulation (2014)

Introduction: Minimal and absent coronary artery calcium (CAC 1-10 and CAC=0) herald a very low risk for cardiovascular disease (CVD) events over 5 years. However, 10-year event rates, and predictors of CVD events in individuals with CAC 1-10 and CAC=0, are unknown.

Methods: MESA is a prospective, contemporary, multi-ethnic cohort of 6,814 subjects aged 45-84 years followed for incident CVD (stroke, MI, cardiac death). CVD event rates were estimated over a median follow-up of 10.3 years in 3,923 subjects with baseline CAC 0-10. Cox proportional hazards models were developed to estimate hazard ratios (HR) for the following baseline risk factors: age, gender, race, lipids, hypertension, diabetes, smoking, family history, CRP, and carotid intima media thickness. Event rates were stratified by 10-year risk categories from the 2013 ACC/AHA pooled ASCVD risk estimator.

Results: There were 123 CVD events over a median follow-up of 10.3 years with an overall event rate of 3.3/1,000 person years. Those with CAC 1-10 (n=508) experienced higher CVD event rates of 5.5/1,000 person years compared to 2.9/1,000 person years in 3,415 subjects with CAC=0 (RR 1.86; 95%CI: 1.16-2.89, p 0.004; Figure). In adjusted Cox models, decade of age (HR 1.65; 95%CI: 1.33-2.05, p<0.001), current smoking (HR 3.33; 95%CI: 2.07-5.35, p<0.001) and hypertension (HR 2.64; 95%CI: 1.71-4.05, p<0.001) significantly predicted CVD. NonHDL-cholesterol significantly predicted CVD only in those with CAC 1-10 (HR 1.54 per SD increase; 95%CI: 1.02-2.32, p 0.04) and not with CAC=0 (HR 1.07; 95%CI: 0.87-1.32, p 0.52). Event rates across risk categories are shown in the Figure.

Conclusions: Ten-year CVD event rates are very low in those with CAC 0-10. Minimal CAC (1-10) nearly doubles the 10-year risk compared with CAC=0 at baseline. Modifiable risk factors including current smoking and hypertension significantly predicted events in this group, while nonHDL-cholesterol only predicted CVD among those with CAC 1-10.

   ![][1]  [1]: /embed/graphic-1.gif
戒烟：戒烟永不嫌晚，即使他们患有肺癌
Authors: Tom, Janet, 江琪琪
Journal: BMJ (2010)

我们是否需要吸烟有害的更多证据？对于心脏疾病、卒中、周围血管疾病和慢性阻塞性肺疾病等常见疾病，吸烟是一个重要因素。此外，大多数肺癌均由吸烟引起，吸烟也是乳腺癌和肠道癌症的危险因素。去年曾有博客称禁烟令是狭隘的和“合理的废话科学”，得到的支持甚微。吸烟损耗生命和身体；吸烟甚至导致过早衰老。
The Mysterious Bird
Authors: Brande Martin
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1715: Elucidating mechanisms of resistance to FGFR inhibitors in endometrial cancer
Authors: Leisl M. Packer, Sara Byron, David Loch, Farhad Dehkhoda, Andreas Wortmann, Xinyan Geng, Katia Nones, Sean Grimmond, John Pearson, Nic Waddell, Pamela Pollock
Journal: Cancer Research (2014)

Abstract Preclinical studies by our lab and others have demonstrated Fibroblast Growth Factor Receptor (FGFR) inhibition is a viable therapeutic strategy in FGFR2-mutant endometrial cancer (EC). A significant clinical issue that we aim to address is that of intrinsic and acquired resistance to anti-FGFR therapeutics in the context of EC. Using mutagenesis screens, we have identified mutations in the FGFR2 kinase domain that cause resistance to the FGFR inhibitors dovitinib and NVP-BGJ398 and explore the mechanism of action of the drug-resistant mutations. We previously reported the N550K and V565I mutations caused resistance to dovitinib. The sensitivity/resistance of these FGFR2 mutants to emerging FGFR inhibitors including AZD4547, NVP-BGJ398 and LY2874455 has now been tested. To gain insights into potential mechanisms of acquired resistance to FGFR inhibitors in EC cells we generated subclones of FGFR2mutant AN3CA, MFE280 and JHUEM-2 EC cells resistant to FGFR inhibitors PD173074, Dovitinib and NVP-BGJ398, respectively. Phospho- protein arrays, gene expression profiling, exome sequencing and SNP analysis were performed to identify genes and signalling pathways that mediate resistance to FGFR inhibitors. Sequencing of AN3CAresistant and MFE280resistant subclones excluded secondary FGFR2 mutations as the resistance mechanisms. Upregulation of downstream survival pathways such as pERK and pAKT was observed in some of the JHUEM-2resistant and AN3CAresistant subclones. To further characterise these subclones we are currently analysing data from exome sequencing and copy number analysis, to determine the molecular mechanisms of resistance in these cell lines. In the MFE280resistant cells resistance to FGFR inhibition is associated with an EMT phenotype. Signaling through pERK and pAKT is downregulated in these cells, suggesting that resistance is not mediated by activation of kinase-driven survival pathways. Analysis of expression data is underway to understand how these cells have become resistant to FGFR inhibitors. This research will provide insight into possible combination therapies that may combat drug resistance in FGFR-mutant endometrial cancer. Citation Format: Leisl M. Packer, Sara Byron, David Loch, Farhad Dehkhoda, Andreas Wortmann, Xinyan Geng, Katia Nones, Sean Grimmond, John Pearson, Nic Waddell, Pamela Pollock. Elucidating mechanisms of resistance to FGFR inhibitors in endometrial cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1715. doi:10.1158/1538-7445.AM2014-1715
MYCOSIS FUNGOIDES WITH "TUMOR d'EMBLÉE": REPORT OF A CASE TREATED WITH NITROGEN MUSTARD
Authors: T S EVANS, A P CIPRIANO, E O HIRSCH
Journal: Annals of Internal Medicine (1950)

Case Reports1 November 1950MYCOSIS FUNGOIDES WITH "TUMOR d'EMBLÉE": REPORT OF A CASE TREATED WITH NITROGEN MUSTARDTHEODORE S. EVANS, M.D., F.A.C.P., ANTHONY P. CIPRIANO, M.D., ERWIN O. HIRSCH, M.D.THEODORE S. EVANS, M.D., F.A.C.P.Search for more papers by this author, ANTHONY P. CIPRIANO, M.D.Search for more papers by this author, ERWIN O. HIRSCH, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-33-5-1294 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe case to be presented possesses several unusual features and even tends to discount the idea, still held by many, that mycosis fungoides is a disease that, with little reservation, is largely confined to the skin throughout its course. As is well known and taught, mycosis fungoides is a relatively rare but chronic and usually fatal disease of the skin, running a rather progressive course with infrequent remissions, and characterized by four well known stages, any or all of which the patient may pass through.The first stage is characterized by generalized pruritus which may persist indefinitely and which may...Bibliography1. Andrews GC: Diseases of the skin, 2nd ed., 1938, W. B. Saunders Company, Philadelphia, page 749. Google Scholar2. JacobsenSpurrBarronSmithLushbaughDick LOCLESTCGF: Nitrogen mustard therapy, J. A. M. A. 132: 263-271, 1946. CrossrefMedlineGoogle Scholar3. Symmers D: Mycosis fungoides as a clinical and pathologic non-existent, Arch. Dermat. and Syph. 25: 1, 1932. CrossrefGoogle Scholar4. Montgomery H: Mycosis fungoides, lymphoblastoma of the skin, and allied conditions as general diseases, Oxford Medicine, Christian and Mackenzie, Vol. 4-336; Section 44: Chapter 1-A, pp. 1-19. Google Scholar5. HenstellToberNewman HHJNBA: The influence of nitrogen mustard on mycosis fungoides, Blood 2: 546, 1947. CrossrefGoogle Scholar6. Nitrogen Mustards: Laboratory and clinical studies from the American Association for the Advancement of Science, Monograph 1947. Google Scholar7. Personal communication from Dr. T. Mallory, Massachusetts General Hospital. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New Haven, Connecticut*Received for publication April 20, 1948.From the Ward Medical Service, Grace Hospital, New Haven, Connecticut. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMycosis fungoidesCytostatica 1 November 1950Volume 33, Issue 5Page: 1294-1302KeywordsMedical servicesPruritusRunningSkin diseases ePublished: 1 December 2008 Issue Published: 1 November 1950 PDF downloadLoading ...
Reversal of adverse effects of neoadjuvant chemotherapy on bone turnover in pre- and post-menopausal women with zoledronic acid
Authors: R. Aft, M. Naughton, K. Trinkuas, M. Watson, K. Weilbaecher
Journal: Journal of Clinical Oncology (2006)

556 Background: Ovarian failure secondary to adjuvant chemotherapy is known to have an adverse effect on bone mineral density and to increase bone turnover markers. The effects of chemotherapy with growth factor support in the absence of hormonal changes have not been described. The impact of zoledronic acid on these changes was also explored. Methods: We evaluated bone turnover markers in 82 women undergoing neoadjuvant chemotherapy for localized stage II/III breast cancer at initial diagnosis prior to treatment and after 4 cycles of epirubicin (75mg/m 2 )-docetaxel (75mg/m 2 ) with pegylated G-CSF support with or without zoledronic acid. 47% of patients were post-menopausal and all groups were balanced for other variables. Women were randomized to receive zoledronic acid 4 mg IV every 3 weeks concurrently with chemotherapy (n=41) versus no bisphosphonate treatment (n=41). Bone turnover markers included: urinary N-telopeptide (NTx), serum bone specific alkaline phosphatase (BAP)and osteocalcin (OSTEO). Results: Women, regardless of menopausal status, who received no bisphosphonate had statistically significant increases in NTx, from baseline after 3 months of neoadjuvant chemotherapy using multivariable mixed repeated measures (p=0.0213). Women who received zoledronic acid concurrently with neoadjuvant chemotherapy had statistically significant decreases in NTx (p&lt;0.0001), BAP (p&lt;0.0001) and OSTEO (p=0.0295) from baseline. This is the first demonstration that anthracycline-taxane chemotherapy with growth factor support increased bone turnover markers in both post-menopausal and pre-menopausal women independent of hormone therapy, radiation therapy and surgery. Conclusions: Neoadjuvant chemotherapy with anthracycline- taxane and growth factor support increased bone resorption markers in both post-menopausal and pre-menopausal women. Zoledronic acid given concurrently with each cycle of chemotherapy reversed this increase in bone turnover markers. No significant financial relationships to disclose.
Appraisal could provide information for revalidation Physican assisted suicide: consensus reached on key issues Many NHS changes have been coordinated by consultants HImPs should be local authority based
Authors: Linda Beecham
Journal: BMJ (2000)

# Appraisal could provide information for revalidation {#article-title-2}

The Central Consultants and Specialists Committee has approved a draft document on appraisal, which will be the basis for discussion with the Department of Health. The committee believes that the process should remain confidential unless concerns about patient safety arise.

The draft sets out the elements which the committee believes an appraisal system for consultants should contain. For example, appraisal should include an evidence based discussion of clinical performance, a confirmation that the doctor has tried to maintain successful professional relationships, and the outcome of investigated complaints.

There should be confirmation of participation in continuing professional development, clinical governance activities, and training in emergency treatment if appropriate. There should be a discussion of professional development and a review of the doctor's job plan.

The CCSC believes that appraisal should be an annual process, although not all issues need to be covered in depth each year. Everyone who acts as an appraiser must receive appropriate training and be on the register. The most appropriate person will be the consultant's clinical director or lead consultant or equivalent.

# Physican assisted suicide: consensus reached on key issues {#article-title-3}

At its consensus conference …
Abstract 5901: The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study
Authors: Paul Gurbel, Kevin Bliden, Mark Antonino, Kathleen Butler, Renli Teng, Lars Rasmussen, Aalborg Sygehus Syd, Robert F Storey, Tonny Nielsen, John Eikelboom, Georges Sabe-Affaki, Steen Husted, Dean Kereiakes, David Henderson, Dharmendra V Patel, Udaya Tantry
Journal: Circulation (2009)

Background: Ticagrelor (T), the first reversibly binding oral P2Y12 receptor antagonist, has been evaluated in patients with ACS in the phase III PLATO trial. The effect of T in patients who are no...
Efficient non-viral vectorisation of siRNA in the brains of newborn mice
Authors: Zahra Hassani, Gregory Lemkine, Patrick Erbacher, Carine Giovannangeli, Jean Paul Behr, Barbara A. Demeneix
Journal: Molecular Therapy (2004)

The recent identification of neural stem cells (NSC) in the subventricular layer of the adult mammalian brain opens up exciting perspectives for therapy of neuro-degenerative diseases. However, the in vivo capacity of neural stem cells to self renew and differentiate are still undefined. A powerful means of investigating the mechanisms regulating NSC biology is RNA interference (RNAi). To exploit the enormous potential of RNAi, efficient in vivo vectorisation methods are needed. Such methods require optimisation for specific delivery routes, tissues and usages. We tested the capacity of different non-viral vectors and formulation methods for inhibition of exogenous (luciferase) gene expression when used to introduce small interfering RNA (siRNA) into the mouse brain in vivo. We used the newborn mouse brain as optimisation is easier and because the radial glial cells that give rise to the adult stem cell population are well characterised and likely targeted by the vectors employed.
METACORTANDRACIN (METICORTEN) IN THE TREATMENT OF DISSEMINATED LUPUS ERYTHEMATOSUS AND PERIARTERITIS NODOSA
Authors: C L STEINBERG, A I ROODENBURG
Journal: Annals of Internal Medicine (1956)

Article1 February 1956METACORTANDRACIN (METICORTEN) IN THE TREATMENT OF DISSEMINATED LUPUS ERYTHEMATOSUS AND PERIARTERITIS NODOSACHARLES LEROY STEINBERG, B.S., M.D., F.A.C.P., ANDRIES I. ROODENBURG, M.D., M.S. (Medicine)CHARLES LEROY STEINBERG, B.S., M.D., F.A.C.P.Search for more papers by this author, ANDRIES I. ROODENBURG, M.D., M.S. (Medicine)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-44-2-316 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDisappointment in the long-term treatment of rheumatic diseases with cortisone and allied steroids has stimulated a search for newer compounds. Two of these compounds are metacortandracin and metacortandralone, which were recently reported as being of value in the treatment of rheumatoid arthritis by Bunim et al.1They recently made preliminary observations on the antirheumatic and anti-inflammatory potency of these synthetic steroids. The structural formula of metacortandracin and metacortandralone and their close relationship to cortisone and hydrocortisone are noted in the figures below. Studies2indicated that these compounds possessed three times the activity of cortisone and twice the activity of hydrocortisone,...Bibliography1. BunimPechetBollet JJMMAJ: Preliminary observations on the antirheumatic potency, metabolic effects, and hormonal properties of metacortandralone and metacortandracin, Proceedings of the First Interim Scientific Session, Bethesda, Maryland, November 4, 1954. Google Scholar2. HerzogNobileTolksdorfCharneyHershbergPerlman HLASWEBPL: New anti-arthritic steroids, Science 121: 176, 1955. CrossrefMedlineGoogle Scholar3. Tumulty PA: The clinical course of systemic lupus erythematosus, J. A. M. A. 156: 947, 1954. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rochester, N. Y.*Received for publication August 8, 1955.From the Arthritis Clinic, The Rochester General Hospital, Rochester, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byProphylaxis in patients receiving adrenal steroid therapyMyocardial infarction following steroid therapy in periarteritis nodosaDas adrenocorticotrope Hormon (ACTH), die HormonederNebenniere(Cortison,Adrenalin) das Insulin, sowie die Hormone der Schilddrüse und NebenschilddrüseMyokarditis und weitere MyokardiopathienKrankheiten der GefäßeSTEROID THERAPY IN COLLAGEN DISEASES. *Periarteriitis nodosaDer viscerale Lupus erythematosus (Kaposi-Libman-Sacks-Syndrom) 1 February 1956Volume 44, Issue 2Page: 316-336KeywordsHospitalsLupus erythematosusPediatricsPhotographyRheumatic feverRheumatoid arthritisSteroids ePublished: 1 December 2008 Issue Published: 1 February 1956 PDF downloadLoading ...
The Internet
Authors: A. Parkin, D. D Stretch
Journal: BMJ (1996)

# Facilities on the Internet may be abused {#article-title-2} EDITOR,—Two recent articles have described the use of electronic mail and the worldwide web.1 2 In his editorial on the Internet Enrico Coiera raises the problem of the disclosure of personal information3; we support what he wrote and offer the following additional comments, which are based on abuses of these facilities that we have witnessed that give rise to serious concerns.
Hypertonic Saline for Prehospital Treatment of Traumatic Brain Injury
Authors: Hans Husum
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal